• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转甲状腺素蛋白(ATTR-CA)和轻链(AL-CA)心脏淀粉样变性患者住院的发生率和原因。

Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis.

机构信息

Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Servicio de Cardiología. Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña, España; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España.

Hospital Universitario Virgen de las Nieves, Granada, España.

出版信息

Med Clin (Barc). 2024 Apr 12;162(7):e1-e7. doi: 10.1016/j.medcli.2024.01.005. Epub 2024 Feb 28.

DOI:10.1016/j.medcli.2024.01.005
PMID:38423944
Abstract

INTRODUCTION AND OBJETIVES

Cardiac amyloidosis (CA) is a disorder associated with high number of hospital admissions. Given the scarce information available, we propose an analysis of the incidence and causes of hospitalization in this disease.

MATERIAL AND METHODS

One hundred and forty-three patients [128 by transthyretin (ATTR-CA) and 15 by light chains (AL-CA)] included in Registro de Amiloidosis Cardiaca de Galicia (AMIGAL) were evaluated, including all hospitalizations.

RESULTS

During a median follow-up of 959 days there were 179 unscheduled hospitalizations [incidence rate (IR) 512.6 admissions per 1000 patients-year], most common due to cardiovascular reasons (n=109, IR 312.2). Most frequent individual cause of hospitalization was heart failure (n=87, TI 249.2). AL-CA was associated with a higher IR of unscheduled hospitalizations than ATTR-CA (IR 781 vs. 483.2; HR 1.62; p=0,029) due to non-cardiovascular admissions (IR 376 vs. 181.2; HR 2.07; p=0.027). Unscheduled admission-free survival at 1 and 3 years in AL-CA was inferior than in ATTR-CA (46.7% and 20.0% vs. 73.4% and 35.2%, respectively; p=0.021).

CONCLUSIONS

CA was associated with high incidence of hospitalizations, being heart failure the most frequent individual cause; unscheduled admission-free survival in AL-CA was lower than in ATTR-CA due mostly to non-cardiovascular admissions.

摘要

简介和目的

心脏淀粉样变(CA)是一种与多次住院相关的疾病。鉴于可用信息有限,我们提出分析该疾病的住院发病率和原因。

材料和方法

评估了 143 名患者[128 名由转甲状腺素(ATTR-CA)和 15 名由轻链(AL-CA)引起],包括所有住院患者。

结果

在中位数为 959 天的随访期间,发生了 179 次非计划住院[发病率(IR)为每 1000 名患者年 512.6 次住院],最常见的原因是心血管原因(n=109,IR 312.2)。最常见的单个住院原因是心力衰竭(n=87,TI 249.2)。由于非心血管住院,AL-CA 的非计划住院 IR 高于 ATTR-CA(IR 781 比 483.2;HR 1.62;p=0.029),IR 376 比 181.2;HR 2.07;p=0.027)。AL-CA 患者在 1 年和 3 年的无计划住院生存分别低于 ATTR-CA(46.7%和 20.0%比 73.4%和 35.2%;p=0.021)。

结论

CA 与高住院率相关,心力衰竭是最常见的单个病因;由于非心血管住院,AL-CA 的无计划住院生存率低于 ATTR-CA。

相似文献

1
Incidence and causes of hospitalization in patients with transthyretin (ATTR-CA) and light chain (AL-CA) cardiac amyloidosis.转甲状腺素蛋白(ATTR-CA)和轻链(AL-CA)心脏淀粉样变性患者住院的发生率和原因。
Med Clin (Barc). 2024 Apr 12;162(7):e1-e7. doi: 10.1016/j.medcli.2024.01.005. Epub 2024 Feb 28.
2
Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center.西班牙转诊中心心脏淀粉样变性的临床特征和转归。
Rev Esp Cardiol (Engl Ed). 2021 Feb;74(2):149-158. doi: 10.1016/j.rec.2019.12.020. Epub 2020 Apr 18.
3
Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors.轻链和转甲状腺素蛋白心脏淀粉样变性:临床特征、自然史和预后因素。
Med Clin (Barc). 2021 Apr 23;156(8):369-378. doi: 10.1016/j.medcli.2020.04.031. Epub 2020 Jun 24.
4
Cardiac amyloidosis: Description of a series of 143 cases.心脏淀粉样变性:143 例系列描述。
Med Clin (Barc). 2022 Sep 9;159(5):207-213. doi: 10.1016/j.medcli.2021.10.018. Epub 2022 Jan 4.
5
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.心脏淀粉样变:被忽视、被低估且可治疗。
Annu Rev Med. 2020 Jan 27;71:203-219. doi: 10.1146/annurev-med-052918-020140.
6
Differences in the characteristics and contemporary cardiac outcomes of patients with light-chain versus transthyretin cardiac amyloidosis.轻链型与转甲状腺素蛋白心脏淀粉样变性患者特征和当代心脏结局的差异。
PLoS One. 2021 Aug 9;16(8):e0255487. doi: 10.1371/journal.pone.0255487. eCollection 2021.
7
Transthyretin amyloid cardiomyopathy.转甲状腺素蛋白淀粉样心肌病。
Med Clin (Barc). 2021 Feb 12;156(3):126-134. doi: 10.1016/j.medcli.2020.06.064. Epub 2020 Oct 31.
8
Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis.轻链和转甲状腺素蛋白心脏淀粉样变性患者心脏起搏器植入的发生率和危险因素。
Eur J Heart Fail. 2022 Jul;24(7):1227-1236. doi: 10.1002/ejhf.2533. Epub 2022 May 16.
9
Prevalence of transthyretin cardiac amyloidosis in elderly patients diagnosed with heart failure.老年心力衰竭患者中甲状腺素运载蛋白心脏淀粉样变性的患病率。
Rev Esp Geriatr Gerontol. 2023 Jan-Feb;58(1):8-14. doi: 10.1016/j.regg.2022.10.005. Epub 2022 Nov 18.
10
Cardiac Amyloidosis Treatment.心脏淀粉样变性的治疗。
Methodist Debakey Cardiovasc J. 2022 Mar 14;18(2):59-72. doi: 10.14797/mdcvj.1050. eCollection 2022.